[Cancer Management and Research] A retrospective review of 30 patients who underwent resection of spinal tumor caused by metastatic SCLC demonstrated that surgery was critical to improving patients QOL and performance status.
Black, Hispanic patients less likely to receive recommended imaging at time of diagnosis of NSCLC.
The accelerated approval was based on data from a prospectively-planned retrospective analysis of 10 cohorts of patients with various previously treated unresectable or metastatic solid tumors with TMB-H who were enrolled in the open-label phase 2 KEYNOTE-158 trial.
Of those eligible for intensive care unit admission, only 10 percent admitted to ICU.
The FDA has approved Zepzelca™ (lurbinectedin; Jazz Pharmaceuticals) for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.